AUG 11, 2026 · JOURNAL ARTICLE
Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209)
Frontiers in Immunology
Single-arm phase 2 trial with encouraging response and survival outcomes in ES-SCLC, but lacks a comparator arm and requires phase 3 validation to establish practice-changing impact.
Reported
Sample size40
Efficacy-evaluable population38
Confirmed objective response rate92.1%